Development Of A Platform Approach To Binding ELISAs
By Lisa Blackwood, Sartorius Stedim BioOutsource
Sartorius has developed a platform approach for binding ELISAs. A binding ELISA is required to demonstrate the functional affinity of a monoclonal antibody, or a monoclonal antibody-like molecule, for its target antigen and is essential in the definition of its mechanism of action. Quantification of the interaction between the Fab antigen recognition site of the antibody and the epitope of the antigen is fundamental in the functional and therapeutic function of mAbs. One method to describe this activity utilises an Indirect ELISA, which involves two binding processes of a primary antibody and a labeled secondary antibody. Shortening the development time for binding ELISAs is crucial to reducing costs associated with speed to market. Here, we demostrate how to reduce the time taken to develop a binding ELISA from over five runs to just two runs for both IgG monoclonal antibodies and Fc fusion proteins.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.